CytomX Therapeutics Inc (CTMX) Stock Analysis
Verdict: AVOID
Severe cash burn ($75.8M FCF loss) and rapid share dilution outweigh oncology pipeline potential, signaling high near-term refinancing risk.
Investment score: 31/100
Analysis as of
Is CytomX Therapeutics Inc stock worth reviewing? AI model thesis
The AI model rates CTMX as an AVOID due to alarming cash burn ($75.8M FCF loss in 2025) relative to cash balance ($12.67M), aggressive share dilution, and consistent quarterly earnings misses.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 25/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
CytomX Therapeutics Inc opportunities and risks
What speaks for CTMX
- Proprietary Probody Platform Collaborations
What speaks against CTMX
- Imminent Capital Raise and Equity Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CTMX | n/a | 33.8x | n/a | 98.6% | -435.2% | -13.3% |
| MDXG | 118.3x | 1.9x | 23.5x | 78.8% | 1.8% | 5.9% |
| CBIO | n/a | 56.4x | n/a | 100.0% | -1371.5% | -22.9% |
| SGMT | n/a | 0.0x | n/a | 0.0% | 0.0% | -11.6% |
| ALT | n/a | 20613.6x | n/a | -48306.5% | -296000.0% | -12.0% |
| MPLT | n/a | 0.0x | n/a | 0.0% | 0.0% | -35.8% |
| Peer median | n/a | 1.9x | n/a | 0.0% | 0.0% | -12.0% |
Frequently asked questions about CytomX Therapeutics Inc (CTMX)
Is CTMX stock a good investment?
The cached TradeMates AI model rates CytomX Therapeutics Inc as AVOID with an investment score of 31/100. The AI model rates CTMX as an AVOID due to alarming cash burn ($75.8M FCF loss in 2025) relative to cash balance ($12.67M), aggressive share dilution, and consistent quarterly earnings misses. This is algorithmic model output, not personal investment advice.
Is CTMX stock a buy?
The TradeMates model verdict for CTMX is AVOID with an investment score of 31/100. Treat this as a model signal to review, not a personal buy recommendation.